Braveheart Bio
- Market cap
- 1.67B
- P/E (TTM)i
- -3.01
- P/Bi
- -17.45
- EPSi
- -0.94
- Div yieldi
- 0.00%
- 52W posi
- 1%
Anonymous reader poll. Unscientific, not investment advice.
Valuation each multiple against its own 5-year range
Vs. peers Biotechnology
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| Braveheart Bio (BRVE) | 1.67B | -3.01 | -17.45 | 0.00% |
| Vertex Pharmaceuticals (VRTX) | 128.16B | 29.45 | 6.33 | 0.00% |
| Moderna (MRNA) | 78.44B | -24.62 | 11.60 | 0.00% |
| Regeneron Pharmaceuticals (REGN) | 76.40B | 18.36 | 2.41 | 0.49% |
| argenx SE (ARGX) | 58.39B | 35.37 | 6.94 | 0.00% |
| Revolution Medicines (RVMD) | 43.05B | -22.65 | 16.52 | 0.00% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 69.2% below Morningstar's fair value estimate.
Fair value
Braveheart Bio Inc earns a 3-star quantitative star rating, indicating our belief that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 32% discount to our quantitative fair value estimate of $31.44 per share; however, caution is warranted due to this estimate's extreme uncertainty rating.
We need more explanatory data to elaborate on this stock's star rating. We strive to explain the factors driving every rating we assign; however, this is not yet possible for a small fraction of our coverage universe.
Economic moat
With its quantitative economic moat rating of none, this business is unlikely to consistently outearn its cost of capital without structural protection from competition.
By Quantitative Equity Report
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.